Multiple System Atrophy Market Share

North America Market Insights

North America in the multiple system atrophy (MSA) market is expected to be the dominant region, with the highest share of 44.7% by the end of 2035. The U.S. is accounting for the majority of the region’s revenue, which is driven by the existence of advanced care infrastructure and strong Medicaid and Medicare coverage, while Canada is simultaneously contributing, which is backed by provincial healthcare funding. As per an article published by NLM in May 2024, a clinical study was conducted on 4,830 participants in the U.S., and 38.7% reported about their telehealth visit, which is also responsible for bolstering the market’s demand in the region.

U.S. MSA market is significantly growing, which is fueled by innovative neurology care hubs and an increase in Medicare and Medicaid expenditures. According to the June 2025 NIH report, there has been an investment of almost USD 48 billion in budget for medical research in the overall region. In addition, nearly 82% of NIH’s funding has been readily awarded for extramural research through 50,000 competitive grants, and 11% of the budget readily supports health and medical projects, which are conducted by almost 6,000 scientists, thereby suitable for the market’s upliftment in the country.

The multiple system atrophy (MSA) market in Canada is also experiencing sufficient development, which is fueled by federal policies for chronic diseases, along with the presence of provincial healthcare investments. As stated in the May 2024 Government of Canada article, USD 200 billion has been allocated for more than 10 years to successfully expand public healthcare. This includes legislation in the Budget Implementation Act 2024, guaranteeing a surge by 5% in Canada Health Transfer payments by the end of 2028. Besides, regional territories and provinces have also received USD 52.1 billion from the federal government, which is also positively impacting the MSA market growth.

APAC Market Insights

Asia Pacific is considered to emerge as the fastest-growing region in the multiple system atrophy (MSA) market during the forecast duration. The market’s upliftment is highly fueled by optimization in diagnostics and an upsurge in the aging population. Japan is leading with the majority of the region’s share, followed by China, owing to an increase in the yearly expenditure growth for rare disorders. India follows closely due to the presence of generic manufacturing which tends to reduce expenses. South Korea has initiated investments for AI diagnostics, while Malaysia has expanded tele-neurology, thus making it suitable for market upliftment in the region.

China’s multiple system atrophy market is gaining increased traction during the forecast period, highly attributed to a surge in the diagnosed patient pool, as well as the evolution in health and medical reforms. Besides, as per the July 2025 NLM article, there has been an upsurge in innovative drug applications from 688 to 2,298 as of 2023, denoting a 35.1% yearly growth. Additionally, there has also been an increase in investigational new drug applications from 627 to 1,918 in the same year, with a growth rate of 32.2%. On the contrary, the NMPA effectively approved 2,461 IND applications, along with 1,918 innovative drugs, thereby making them suitable for the market’s exposure.

The multiple system atrophy market in India is also witnessing development, which is effectively driven by an upsurge in the patient population, along with the generic drug dominance. Additionally, the aspect of government expenditure is also a huge driver for uplifting the market in the country. For instance, as per the January 2025 PIB report, there has been a generous increase in the government healthcare expenditure from 29.0% to 48.0% by the end of 2022. This resulted in Ayushman Yojana diminishing out-of-pocket expenses and saving more than Rs. 1.2 Lakh Crore (approximately USD 14.4 billion), thus bolstering the market’s development.

Innovative Drug Growth and Population Distribution Driving the Market in the Asia Pacific

Sources: NLM; APAC Med

Europe Market Insights

Europe market is regarded to account for a considerable share by the end of the projected duration, which is effectively propelled by the presence of centralized health and medical systems and a rise in the aging population. Germany is leading the region, with the majority of the revenue share, which is driven by yearly expenditure on MSA therapies, along with the presence of specialized neurology centers. This is followed by the UK, with NHS budget allocation for MSA care. Furthermore, France has also made its contribution by prioritizing early diagnosis and investing in its overall health budget, thus suitable for uplifting the market in the region.

The multiple system atrophy (MSA) market in Germany is readily dominating the region, which is propelled by an increase in the annual spending on treatments and diagnosis. As stated in the November 2023 ISPOR Organization data report, an additional discount of 20% has been provided in the G-Bas list of combination products including €10,000 for manufacturing expenses and €15,000 for industrial expenses for drug development. Besides, in the case of over 20% vial wastage for patients, manufacturers are bound to make payment for the wastage, thus suitable for boosting the MSA market in the country.

The multiple system atrophy (MSA) market in the UK is gaining increased exposure which is backed by NHS provision of its neurology budget, accounting for generous amount. As per an article published by the UK Government in June 2025, the Chancellor has readily declared £29 billion investment, with the intention of rebuilding the National Health Service. This further includes, latest investment of £10 billion on digital and technological transformation, while the Chancellor also confirmed £11 billion in defense to ensure suitable security to the organization, which is essential for bolstering the market in the country.

2022 Healthcare Expenditure in Europe

Source: World Bank Organization